Recent progress in the pharmacotherapy of Churg-Strauss syndrome

Expert Opinion on Pharmacotherapy

Volumn 5, Issue 1, 2004, Pages 25-35

  Hellmich, Bernhard ^a   Gross, Wolfgang L ^b  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b Rheumaklinik Bad Bramstedt   (Germany)

Author keywords

Churg Strauss syndrome; Cyclophosphamide; Interferon ; Methotrexate; Treatment

Indexed keywords

AZATHIOPRINE; BUDESONIDE; CARBAMAZEPINE; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ETANERCEPT; FLUTICASONE; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; INTERLEUKIN 5 ANTIBODY; MACROLIDE; MESNA; METHOTREXATE; METHYLPREDNISOLONE; MONTELUKAST; PRANLUKAST; PREDNISOLONE; RECOMBINANT ALPHA INTERFERON; SALMETEROL; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR; VERLUKAST; ZAFIRLUKAST; ZILEUTON;

ASTHMA; BLADDER CANCER; CHURG STRAUSS SYNDROME; CLINICAL FEATURE; CLINICAL TRIAL; CORTICOSTEROID INDUCED OSTEOPOROSIS; CUSHING SYNDROME; DISEASE CONTROL; DISEASE SEVERITY; DRUG CHOICE; DRUG EFFICACY; DRUG MEGADOSE; EOSINOPHILIA; FRAGILITY FRACTURE; HEMORRHAGIC CYSTITIS; HUMAN; HYPERADRENOCORTICISM; HYPOGONADISM; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFECTION; INFECTION RISK; LEUKOENCEPHALOPATHY; LEUKOPENIA; LONG TERM CARE; MYOPATHY; PNEUMOCYSTIS PNEUMONIA; PROGNOSIS; PSYCHOSIS; RELAPSE; REMISSION; REVIEW; SHORT COURSE THERAPY; SYSTEMIC VASCULITIS; TREATMENT FAILURE; TREATMENT OUTCOME;

ADRENAL CORTEX HORMONES; ANGIOGENESIS INHIBITORS; ANTI-ASTHMATIC AGENTS; ASTHMA; CHURG-STRAUSS SYNDROME; CYCLOPHOSPHAMIDE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-ALPHA; METHOTREXATE; PLASMAPHERESIS;

EID: 0347286796     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.5.1.25     Document Type: Review

References (79)

1. CHURG JSL: Allergic granulomatosis, allergic angiitis, and periarteritis nodosa. Am. J. Pathol. (1951) 27:272-301.
2. GROSS W: Churg-Strauss syndrome: update on recent developments. Curr. Opin. Rheumatol. (2002) 14:11-14.
3. CHUMBLEY LC, HARRISON EG Jr, DEREMEE RA: Allergic granulomatosis and angiitis (Churg-Strauss syndrome). Report and analysis of 30 cases. Mayo Clin. Proc. (1977) 52:477-484.
4. LANHAM J, ELKON K, PUSEY C, HUGHES G: Systemic vasculitis with asthma and eosinophilia: a clinical approach to the Churg-Strauss syndrome. Medicine (1984) 63:65-81.
5. NOTH I, STREK M, LEFF A: Churg-Strauss syndrome. Lancet (2003) 361:587-594.
6. NAGASHIMA T, CAO B, TAKEUCHI N et al.: Clinicopathological studies of peripheral neuropathy in Churg-Strauss syndrome. Neuropathology (2002) 22:299-307.
7. GUILLEVIN L, COHEN P, GAYRAUD M et al.: Churg-Strauss syndrome. Clinical study and long-term follow-up of 9 6 patients. Medicine (1999) 78:26-37.
8. SOLANS R, BOSCH JA, PEREZ-BOCANEGRA C et al.: Churg-Strauss syndrome: outcome and long-term follow-up of 32 patients. Rheumatology (2001) 40:763-771.
9. LILLY C, CHURG A, LAZAROVICH M et al.: Asthma therapies and Churg-Strauss syndrome. J. Allergy Clin. Immunol. (2002) 109:S1-S20.
10. CONRON M, BEYNON H: Churg-Strauss syndrome. Thonax (2000) 55:870-877.
11. POTTER M, FINCHER R, FINGER D: Eosinophilia in Wegener's granulomatosis. Chest (1999) 116:1480-1483.
12. GROSS W, SCHMITT W, CSERNOK E: ANCA and associated diseases. immunodiagnostic and pathogenetic aspects. Clin. Exp. Immunol. (2001) 91:1-2.
13. HOFFMAN GS: Classification of the systemic vasculitides. Clin. Exp. Rheumatol. (1998) 16:111-115.
14. GROSS WL, SCHNABEL A, TRABANDT A: New perspectives in pulmonary angiitis. From pulmonary angiitis and granulomatosis to ANCA associated vasculitis. Sarcoidosis Vasc. Diffuse Lung Dis. (2000) 17:33-52.
15. GUILLEVIN L, VISSER H, NOEL LH et al.: Antineutrophil cytoplasm antibodies in systemic polyarteritis nodosa with and without hepatitis B virus infection and Churg-Strauss syndrome - 62 patients. J. Rheumatol. (1993) 20:1345-1349.
16. KALLENBERG CG, MULDER AH, TERVAERT JW: Antineutrophil cytoplasmic antibodies: a still-growing class of autoantibodies in inflammatory disorders. Am. J. Med. (1992) 93:675-682.
17. HOFFMAN GS, SPECKS U: Antineutrophil cytoplasmic antibodies. Arthritis Rheum. (1998) 41:1521-1537.
18. EUSTACE J, NADASDY T, CHOI M: Churg-Strauss syndrome. J. Am. Soc. Nephrol. (1999) 10:2048-2055.
19. ARBACH O, CSERNOK E, GROSS W, GAUSE A: Is the Churg-Strauss Syndrome an ANCA-associated vasculitis? Cleveland Clin. J. Med. (2002) 69:173-174.
20. HELLMICH B, CSERNOK E, GROSS W: 20 years with ANCA (antineutrophil cytoplasmic antibodies): from seromarker to major pathogenic player in vasculitis. J. Leukoc. Biol. (2003) 74:1-2.
21. MASI AT, HUNDER GG, LIE JT et al.: The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum. (1990) 33:1094-1100.
22. JENNETTE J, ANDRASSY K, BACON PA et al.: Nomendature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum. (1994) 37:187-192.
23. LANE SE, WATTS RA, BARKER TH, SCOTT DG: Evaluation of the Sorensen diagnostic criteria in the classification of systemic vasculitis. Rheumatology (2002) 41:1138-1141.
24. LEAVITT R, FAUCI A, BLOCH D et al.: The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. Arthritis Rheum. (1990) 33:1101-1107.
25. RAO J, ALLEN N, PINCUS N: Limitations of the 1990 American College of Rheumatology classification criteria in the diagnosis of vasculitis. Ann. Intern. Med. (1998) 129:345-352.
26. SORENSEN SF, SLOT O, TVEDE N, PETERSEN J: A prospective study of vasculitis patients collected in a five year period: evaluation of the Chapel Hill nomendature. Ann. Rheum. Dis. (2000) 59:478-482.
27. CHURG A, BRALLAS M, CRONIN S, CHURG J: Formes frustes of Churg-Strauss Syndrome. Chest (1995) 108:320-323.
28. REINHOLD-KELLER E, ZEIDLER A, GUTFLEISCH J et al.: Giant cell arteritis is more prevalent in urban than in rural populations: results of an epidemiological study of primary systemic vasculitides in Germany. Rheumatology (2000) 39:1396-1402.
29. WATTS R, CARRUTHERS D, SCOTT D: Epidemiology of systemic vasculitis: Changing incidence or definition. Semin. Arthritis Rheum. (1995) 25:28-34.
30. REINHOLD-KELLER E, HERLYN K, WAGNER-BASTMEYER R et al.: No difference in the incidences of vasculitides between north and south Germany: first results of the german vasculitis register. Rheumatology (2002) 41:540-549.
31. LOUGHLIN J, COLE J, ROTHMAN K, JOHNSON E: Prevalence of serious eosinophilia and incidence of Churg-Strauss syndrome in a cohort of asthma patients. Ann. Allergy Asthma Immunol. (2002) 98:319-325.
32. HELLMICH B, EHLERS S, CSERNOK E, GROSS W: Update on the pathogenesis of Churg-Strauss syndrome. Clin. Exp. Rheumatol. (2003) (In Press).
33. MUSCHEN M, WARSKULAT U, PERNIOK A et al.: Involvement of soluble CD95 in Churg-Strauss syndrome. Am. J. Pathol. (1999) 155:915-925.
34. SCHONERMARCK U, CSERNOK E, TRABANDT A, HANSEN H, GROSS WL: Circulating cytokines and soluble CD23, CD26 and CD30 in ANCA-associated vasculitides [In Process Citation]. Clin. Exp. Rheumatol. (2000) 18:457-463.
35. KIENE M, CSERNOK E, MULLER A et al.: Elevated interleukin-4 and interleukin-13 production by T cell lines from patients with Churg-Strauss syndrome. Arthritis Rheum. (2001) 44:469-473.
36. SIWEK J, GOURLAY ML, SLAWSON DC, SHAUGHNESSY AF: How to write an evidence-based clinical review article. Am. Fam. Physician (2002) 65:251-258.
37. MALERBA M, ROMANELLI G, GRASSI V: Glucocorticoid-induced osteoporosis in asthma and respiratory diseases. Front Horm. Res. (2002) 30:86-93.
38. CONRON M, BEYNON HL: Churg-Strauss syndrome. Thorax (2000) 55:870-877.
39. GAYRAUD M, GUILLEVIN L, COHEN P et al.: Treatment of good-proposis polyarteritis nodosa and Churg-Strauss syndrome: comparison of steroids and oral or pulse cyclophosphamide in 25 patients. French Cooperative Study Group for Vasculitides. Br. J. Rheumatol. (1997) 36:1290-1297.
40. GUILLEVIN L, JARROUSSE B, LOK C et al.: Longterm-followup after treatment of polyarteriitis nodosa and Chrug-Strauss angiitis with comparison of steroids, plasma exchange and cyclophosphamide to steroids and plasma exchange. A prospective randomized trial of 71 patients. The cooperative Study Group for Polyarteritis nodosa. J. Rheumatol. (1991) 18:567-574.
41. LANGFORD CA: Treatment of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: where do we stand? Arthritis Rheum. (2001) 44:508-512.
42. GAYRAUD M, GUILLEVIN L, LE TOUMELIN P et al.: Long-term followup of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: analysis of four prospective trials including 278 patients. Arthritis Rheum. (2001) 44:666-675.
43. HOFFMAN G: Treatment of Wegener's granulomatosis: time to change the standard of care? Arthritis Rheum. (1997) 40:2099-2104.
44. DE GROOT K: Randomised controlled trials and new drugs. Ann. Rheum. Dis. (2003) 62:53.
45. BRADLEY JD, BRANDT KD, KATZ BP: Infectious complications of cyclophosphamide-induced severe neutropenia in Wegener's granulomatosis. Arthritis Rheum. (1989) 32:45-53.
46. DRAKE MJ, NIXON PM, CREW JP: Drug-induced bladder and urinary disorders. Incidence prevention and management. Drug Saf. (1998) 19:45-55.
47. APTEKAR RG, ATKINSON JP, DECKER JL, WOLFF SM, CHU EW: Bladder toxicity with chronic oral cyclophosphamide therapy in nonmalignant disease. Arthritis Rheum. (1973) 16:461-467.
48. JAYNE D, RASMUSSEN N, ANDRASSY K et al.: A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N. Engl. J. Med. (2003) 349:36-44.
49. HASELBERGER MB, SCHWINGHAMMER TL: Efficacy of mesna for prevention of hemorrhagic cystitis after high-dose cyclophosphamide therapy. Ann. Pharmacother. (1995) 29:918-921.
50. SNELLER MC, HOFFMAN GS, TALAR-WILLLAMS C et al.: An analysis of forty-two Wegener's granulomatosis patients treated with methotrexate and prednisone. Arthritis Rheum. (1995) 38:608-613.
51. REINHOLD-KELLER E, FINK C, HERLYN Y, GROSS WL, DE GROOT K: High rate of renal relapse in 71 patients with Wegener's granulomatosis under maintance of remission with low-dose methotrexate. Arthritis Care Res. (2002) 47:326-332.
52. BOCKENSTEDT PL, SANTINGA JT, BOLLING SF: alpha-Interferon treatment for idiopathic hypereosinophilic syndrome. Am. J. Hematol. (1994) 45:248-251.
53. MOHR C, SCHUTTE B, HILDEBRAND A, LUGER TA, KOLDE G: Eosinophilic pustular folliculitis: successful treatment with interferon-alpha. Dermatology (1995) 191:257-259.
54. HUSAK R, GOERDT S, ORFANOS CE: Interferon alfa treatment of a patient with eosinophilic cellulitis and HIV infection. N. Engl. J. Med. (1997) 337:641-642.
55. TATSIS E, SCHNABEL A. GROSS W: Interferon-Alpha treatment of four patients with the Churg-Strauss syndrome. Ann. Intern. Med. (1998) 1239:370-374.
56. LESENS O, HANSMANN Y, NERSON J et al.: Severe Churg-Strauss syndrome with mediastinal lymphadenopathy treated with interferon therapy. Eur. J. Intern. Med. (2002) 13:458.
57. TERMEER CC, SIMON JC, SCHOPF E: Low-dose interferon alfa-2b for the treatment of Churg-Strauss syndrome with prominent skin involvement. Arch. Dermatol. (2001) 137:136-138.
58. REISSIG A. FORSTER M, MOCK B, SCHILDER C, KROEGEL C: [Interferon-alpha treatment of the Churg-Strauss syndrome]. Dtsch. Med. Wochenschr. (2003) 128:1475-1478.
59. HELLMICH B, GROSS WL: [Churg-Strauss syndrome following treatment with leukotriene receptor antagonists: demasking by steroid taper or side effect?]. Dtsch. Med. Wochenschr. (2003) 128:1469.
60. KRISHNASWAMY G, SMITH JK, SKIKANTH S et al.: Lymphoblastoid interferon-alpha inhibits T cell proliferation and expression of eosinophil-activating cytokines. J. Interferon Cytokine Res. (1996) 16:819-827.
61. ALDEBERT D, LAMKHIOUED B, DESAINT C et al.: Eosinophils express a functional receptor for interferon alpha: inhibitory role of interferon alpha on the release of mediators. Blood (1996) 87:2354-2360.
62. PORRES JC, CARRENO V, RUIZ M, MARRON JA, BARTOLOME J: Interferon antibodies in patients with chronic HBV infection treated with recombinant interferon. J. Hepatol. (1989) 8:351-357.
63. STANCEK D, FUCHSBERGER. N, OLTMAN M et al.: Significance of anti-interferon-alpha2 and sICAM-1 activities in the sera of viral hepatitis B and C patients treated with human recombinant interferon-alpha2. Acta Virol. (2001) 45:287-292.
64. GUILLEVIN L, FAIN O, LHOTE F et al.: Lack of superiority of steroids plus plasma exchange to steroids alone in die treatment of polyarteriitis nodosa and Churg-Strauss syndrome. a prospective, randomized trial in 78 patients. Arthritis Rheum. (1992) 35:208-215.
65. GUILLEVIN L, LHOTE F, COHEN F et al.: Corticosteroids plus pulse cyclophosphamide and plasma exchanges versus corticosteroids plus pulse cyclophosphamide alone in the treatment of polyarteriitis nodosa and Churg-Strauss syndrome patients with factors predicting poor prognosis. A prospective, randomized trial in sixty-two patients. Arthritis Rheum. (1995) 38:1638-1645.
66. ARBACH O, GROSS W, GAUSE A: Treatment of refractory Churg-Strauss-Syndrome (CSS) by TNF-alpha blockade. Immunobiology (2002) 206:496-501.
67. HAMILOS DL, CHRISTENSEN J: Treatment of Churg-Strauss syndrome with high-dose intravenous immunoglobulin. J. Allergy Clin. Immunol. (1991) 88:823-824.
68. LEVY Y, GEORGE J, FABBRIZZI F et al.: Marked improvement of Churg-Strauss vasculitis with intravenous gammaglobulins. South. Med. J. (1999) 92:412-414.
69. REID AJ, HARRISON BD, WATTS RA et al.: Churg-Strauss syndrome in a district hospital. QJM (1998) 91:219-229.
70. MCDERMOTT EM, POWELL RJ: Cyclosporin in the treatment of Churg-Strauss syndrome. Ann. Rheum. Dis. (1998) 57:258-259.
71. THOMSON D, CHAMSI-PASHA H, HASLETON P: Heart transplantation for Churg-Strauss syndrome. Br. Heart J. (1989) 62:409-410.
72. LECKIE MJ, TEN BRINKE A, KHAN J et al.: Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet (2000) 356:2144-2148.
73. O'BYRNE PM, INMAN MD, PARAMESWARAN K: The trials and tribulations of IL-5, eosinophils, and allergic asthma. J. Allergy Clin. Immunol. (2001) 108:503-508.
74. WECHSLER ME, FINN D, GUNAWARDENA D et al.: Churg-Strauss syndrome in patients receiving montelukast as treatment for asthma. Chest (2000) 117:708-713.
75. WELLER PF, PLAUT M, TAGGART V, TRONTELL A: The relationship of asthma therapy and Churg-Strauss syndrome. NIH workshop summary report. J. Allergy Clin. Immunol. (2001) 108:175-183.
76. JAMALEDDINE G, DIAB K, TABBARAH Z, TAWIL A, ARAYSSI T: Leukotriene antagonists and the Churg-Strauss syndrome. Semin. Arthritis Rheum. (2002) 31:218-227.
77. GEKELER V, ISE W, SANDERS K, ULRICH W, BECK J: The leukotriene LTD4 receptor antagonist MK571 specifically modulates MRP associated multidrug resistance. Biochem. Biophys. Res. Commun. (1995) 208:345-352.
78. PRECHTL S, ROELLINGHOFF M, SCHEPER R et al.: The multidrug resistance protein 1: a functionally important activation marker for murine Th1 cells.J. Immunol. (2000) 164:754-761.
79. ROBBIANI D, FINCH R, JAGER D et al.: The leukotriene C4 transporter MRP1 regulates CCL19 (MIP-3beta ELC)-dependent mobilization of dendrtitic cells to lymph nodes. Cell (2000) 103:757-768.